Growing Concerns: GLP-1 RAs and the Link to Thyroid Cancer
The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in treating type 2 diabetes (T2D) has exploded in recent years. These medications are lauded for their effectiveness in managing blood sugar levels and for offering additional cardiovascular benefits. They have even shown promise in improving kidney function and combating fatty liver disease.
However, a burgeoning cloud of uncertainty has descended upon this promising treatment avenue: a potential link to thyroid cancer. This concern stems from preclinical studies conducted on rodents which suggested a possible association between GLP-1 RAs and medullary thyroid cancer. This triggered a precautionary warning from the US Food and Drug Administration (FDA), advising individuals with a personal or family history of medullary thyroid cancer to avoid these medications.
This FDA warning spurred a wave of research aimed at understanding the implications for humans.
A recent study published in JAMA Otolaryngol Head Neck Surgery delved into this complex issue. Researchers, led by Dr. Rozalina G. McCoy from the University of Maryland School of Medicine, analyzed a massive dataset of nearly 352,000 adults with T2D at risk for cardiovascular disease.
The study compared the rates of thyroid cancer diagnoses in patients using GLP-1 RAs with those using other diabetes medications, such as SGLT2 inhibitors, DPP4 inhibitors, and sulfonylureas. The team leveraged linked administrative claims data from commercial, Medicare Advantage, and Medicare fee-for-service plans, spanning from 2014 to 2021.
While the study identified a potential association between GLP-1 RA use and thyroid cancer risk, particularly within the first year of treatment, Dr. McCoy and her colleagues emphasized the need for further investigation before establishing a definitive causal link.
Another intriguing finding emerged from the study: patients using GLP-1 RAs had a higher frequency of thyroid ultrasonography during the first six and twelve months compared to those using other medications. This suggests that increased screening practices among GLP-1 RA users could be contributing to the observed rise in thyroid cancer diagnoses.
"Patients treated with GLP-1RA had higher thyroid ultrasonography utilization at 6 and 12 months compared to those receiving non-GLP-1RA medications, suggesting that detection bias was behind the increased cancer diagnosis rate observed among patients treated with a GLP-1RA within the first year of therapy,” the researchers noted.
Interview with Dr. Rozalina G. McCoy:
Archyde: Dr. McCoy, GLP-1 RAs have gained immense popularity for treating type 2 diabetes, showcasing significant benefits for cardiac health and other metabolic conditions. However, recent concerns regarding a possible association with thyroid cancer have cast a shadow over their widespread use. Could you shed some light on this developing issue?
Dr. McCoy: Absolutely. GLP-1 RAs have revolucionized diabetes management, offering remarkable benefits for patients. However, preclinical studies in rodents did raise concerns about a potential link to medullary thyroid cancer. This prompted the FDA to issue a boxed warning advising individuals with a personal or family history of medullary thyroid cancer to avoid these medications. This uncertainty spurred further research to understand the human implications.
Archyde: Your recent study published in JAMA Otolaryngol Head Neck Surgery analyzed a large dataset of patients with type 2 diabetes and investigated the incidence of thyroid cancer among those using GLP-1 RAs compared to other diabetes medications. What were your key findings?
Dr. McCoy: Our study analyzed data from nearly 352,000 adults with type 2 diabetes at risk for cardiovascular disease. We observed a possible association between GLP-1 RA use and thyroid cancer risk, particularly within the first year of treatment. However, it is crucial to emphasize that this association does not necessarily indicate a causal relationship. We also noted a higher frequency of thyroid ultrasonography among patients using GLP-1 RAs during the initial months of treatment compared to those using other medications. This suggests that increased screening practices might be contributing to the observed rise in thyroid cancer diagnoses.
Archyde: So, the observed increase in diagnoses could be attributed to more frequent screening rather than a direct causal link between GLP-1 RAs and thyroid cancer?
Dr. McCoy: That’s precisely why further research is essential. While our findings highlight a potential link that warrants further investigation, the overall analysis suggests that there is low confidence in a causal relationship between thyroid cancer and GLP-1 RAs, especially considering the timeline of the association.
Archyde: What are your recommendations for patients currently using GLP-1 RAs? Should they be concerned?
Dr. McCoy: At this stage, it’s crucial to prioritize open communication with your healthcare provider. They can assess your individual risk factors, discuss the potential benefits and risks of GLP-1 RA therapy, and guide you on the most appropriate course of action. Continue to adhere to your prescribed treatment plan unless advised otherwise by your doctor.
Archyde: What future research directions are crucial to definitively address this issue and provide clarity for both patients and clinicians?
Dr. McCoy: We need to conduct larger-scale, prospective studies specifically designed to investigate the long-term effects of GLP-1 RA use on thyroid health. These studies should also focus on understanding the underlying mechanisms behind any observed associations. Additionally, further research is needed to determine if the benefits of GLP-1 RAs outweigh the potential risks for individuals with a history of thyroid disease.
Archyde: Thank you, Dr. McCoy, for shedding light on this complex issue. It’s clear that continued research is essential to fully understand the relationship between GLP-1 RAs and thyroid cancer.